Participant baseline variables by response status after 12 months
| N | % or mean (SD) | Target achieved (sUA <360 µmol/L) N=159 | Target not achieved (sUA >360 µmol/L) N=27 | P value | |
| Age (years) | 186 | 56.8 (13.6) | 57.4 (13.5) | 53.5 (13.4) | 0.17 |
| Male | 186 | 95.2% | 94.3% | 100% | 0.21 |
| White | 180 | 90.6% | 91.6% | 84.6% | 0.26 |
| Disease duration (years) | 182 | 8.2 (7.) | 8.0 (7.8) | 9.4 (8.3) | 0.42 |
| Education level college | 182 | 60.4% | 61.5% | 53.8% | 0.46 |
| Married/cohabiting | 183 | 77.0% | 77.7% | 73.1% | 0.60 |
| Working versus not | 183 | 66.7% | 66.9% | 65.9% | 0.52 |
| Body mass index | 186 | 28.9 (4.6) | 28.8 (4.6) | 29.6 (4.5) | 0.41 |
| Comorbidities (SCQ sum) | 185 | 3.8 (3.3) | 3.9 (3.3) | 3.0 (3.3) | 0.18 |
| Physical activity >3 times weekly | 182 | 33.0% | 33.8% | 28.0% | 0.57 |
| Smoking, daily | 183 | 8.2% | 7.6% | 11.5% | 0.93 |
| Alcohol consumption (at least weekly) | 182 | 61.5% | 59.0% | 76.9% | 0.08 |
| Sugar sweetened drinks consumed daily | 182 | 37.9% | 38.5% | 34.6% | 0.71 |
| Tophus present (>1) | 186 | 16.7% | 18.2% | 7.4% | 0.16 |
| Allopurinol ever use | 186 | 14.0% | 13.8% | 14.8% | 0.90 |
| NSAID ever use | 180 | 79.4% | 77.9% | 88.5% | 0.22 |
| Colchicine ever use | 177 | 52.5% | 53.0% | 50.0% | 0.78 |
| Prednisolone ever use | 176 | 49.4% | 49.7% | 48.0% | 0.88 |
| Baseline sUA (µmol/L) | 186 | 498 (80) | 495 (72) | 517 (117) | 0.36 |
| ESR (mm/hour) | 176 | 14 (14) | 14 (14) | 16 (14) | 0.57 |
| Creatinine (µmol/L) | 186 | 96 (18) | 96 (17) | 98 (18) | 0.55 |
| eGFR (mL/min) | 185 | 78 (18) | 78 (18) | 79 (20) | 0.69 |
| No. flares before recent one | 187 | 0.82 | |||
| 0–1 | 34 | 18.6% | 17.9% | 23.0% | |
| 2–5 | 53 | 29.0% | 29.3% | 26.0% | |
| >5 | 96 | 52.5% | 52.9% | 50.0% | |
| Other flare last 12 months before inclusion | 181 | 75.1% | 74.2% | 80.8% | 0.79 |
| Strongest joint pain ever (0–10) | 183 | 8.3 (1.6) | 8.4 (1.5) | 8.1 (2.0) | 0.48 |
| Joint pain last flare (0–10) | 182 | 7.1 (2.0) | 7.1 (1.9) | 7.4 (2.4) | 0.40 |
| Swollen joint present | 184 | 35.3% | 35.7% | 33.3% | 0.82 |
| Tender joint present | 184 | 53.3% | 53.5% | 51.9% | 0.87 |
| Health Assessment Questionnaire | 184 | 0.36 (0.57) | 0.33 (0.54) | 0.56 (0.71) | 0.13 |
| SF-36 physical component summary (0–100) | 182 | 38.9 (10.8) | 39.2 (10.5) | 37.1 (12.4) | 0.38 |
| SF-36 mental component summary (0–100) | 182 | 50.4 (10.1) | 50.5 (10.5) | 50.2 (7.6) | 0.89 |
| Self-efficacy pain (10–100) | 184 | 65.3 (19.2) | 65.6 (19.1) | 63.9 (20.1) | 0.68 |
| Self-efficacy symptoms (10–100) | 180 | 72.8 (17.0) | 73.7 (16.9) | 66.9 (17.2) | 0.06 |
| Beliefs about Medicines Questionnaire | |||||
| Necessity (5–25) | 176 | 17.0 (4.3) | 17.0 (4.3) | 16.7 (4.5) | 0.74 |
| Concern (5–25) | 175 | 13.4 (4.4) | 13.4 (4.5) | 13.3 (3.7) | 0.92 |
| Overuse (4–16) | 179 | 10.6 (2.8) | 10.4 (2.7) | 11.6 (2.7) | 0.04 |
| Harm (4–16) | 179 | 9.4 (2.4) | 9.3 (2.5) | 10.0 (2.0) | 0.18 |
eGFR, electronic glomerular filtration rate; ESR, erythrotcyte sedimentation rate; NSAID, non-steroidal anti-inflammatory drug; SCQ, Self-Administered Comorbidity Questionnaire; SF-36, Short-form 36.